TapewireFind a company

person · Reporting owner

Hughes-Wilson Alexandra

Disclosed activity across 1 company

Tapewire entity
68234
SEC CIK
0002005875

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Mereo BioPharma Group plcMREO · Entity 7264See RemarksFebruary 01, 2026February 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Mereo BioPharma Group plc

Report date February 01, 2026 · Filed February 02, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Share Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.44 · Expires 2036-02-01Direct183,750 Reported balance After 2026-02-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-02-01 · Grant · Acquired 183,750 · Balance 183,750

F1: 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter.

F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Share Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2036-02-01Direct61,250 Reported balance After 2026-02-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-02-01 · Grant · Acquired 61,250 · Balance 61,250

F1: 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter.

F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Share Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.44 · Expires 2036-02-01Direct195,000 Reported balance After 2026-02-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-02-01 · Grant · Acquired 195,000 · Balance 195,000

F3: Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date.

F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter.

F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F3: Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 01, 2026 Filed Feb 2, 2026 16:30 UTC Mereo BioPharma Group plc MREO · Entity 7264 GrantShare Options (Right to buy) · Derivative 195,000 $0.00 Strike: $0.44 $0.00
Disclosure

SEC source: 0001193125-26-033753 · ownership.xml · derivative · entry 3

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 195,000

Underlying: American Depository Shares · 195,000 shares

Expires 2036-02-01

F3 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date.

F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Read SEC document
February 01, 2026 Filed Feb 2, 2026 16:30 UTC Mereo BioPharma Group plc MREO · Entity 7264 GrantShare Options (Right to buy) · Derivative 61,250 $0.00 Strike: $1.00 $0.00
Disclosure

SEC source: 0001193125-26-033753 · ownership.xml · derivative · entry 2

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,250

Underlying: American Depository Shares · 61,250 shares

Expires 2036-02-01

F1 · derivative.exercise_date: 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter.

F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Read SEC document
February 01, 2026 Filed Feb 2, 2026 16:30 UTC Mereo BioPharma Group plc MREO · Entity 7264 GrantShare Options (Right to buy) · Derivative 183,750 $0.00 Strike: $0.44 $0.00
Disclosure

SEC source: 0001193125-26-033753 · ownership.xml · derivative · entry 1

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 183,750

Underlying: American Depositary Shares · 183,750 shares

Expires 2036-02-01

F1 · derivative.exercise_date: 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter.

F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Read SEC document
January 25, 2025 Filed Jan 28, 2025 16:05 UTC Mereo BioPharma Group plc MREO · Entity 7264 GrantShare Options (Right to buy) · Derivative 154,000 $0.00 Strike: $2.91 $0.00
Disclosure

SEC source: 0000950170-25-009789 · ownership.xml · derivative · entry 1

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,000

Underlying: American Depository Shares · 154,000 shares

Expires 2035-01-25

F1 · derivative.exercise_date: 25% of the shares underlying this share option will vest and become exercisable on January 25, 2026, with the remainder vesting in equal monthly installments for the three years thereafter.

F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Read SEC document
September 13, 2024 Filed Sep 16, 2024 20:46 UTC Mereo BioPharma Group plc MREO · Entity 7264 SaleAmerican Depositary Shares representing Ordinary Shares 84,008 $4.22 $354,597.77
Disclosure

SEC source: 0000950170-24-106968 · ownership.xml · nonDerivative · entry 4

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,475

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F5 · shares: The Reporting Person sold a total of 124,037 ADSs solely to pay tax obligations, including tax withholding obligations related to the exercise of stock options described in the Form 4 filed on September 13, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.01 to $4.43, inclusive.

Read SEC document
September 13, 2024 Filed Sep 16, 2024 20:46 UTC Mereo BioPharma Group plc MREO · Entity 7264 SaleAmerican Depositary Shares representing Ordinary Shares 16,304 $4.22 $68,819.18
Disclosure

SEC source: 0000950170-24-106968 · ownership.xml · nonDerivative · entry 3

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,483

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F2 · shares: Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the 'Plan'), occurring on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.01 to $4.43, inclusive.

Read SEC document
September 12, 2024 Filed Sep 16, 2024 20:46 UTC Mereo BioPharma Group plc MREO · Entity 7264 SaleAmerican Depositary Shares representing Ordinary Shares 40,029 $4.47 $179,037.71
Disclosure

SEC source: 0000950170-24-106968 · ownership.xml · nonDerivative · entry 2

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,787

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F5 · shares: The Reporting Person sold a total of 124,037 ADSs solely to pay tax obligations, including tax withholding obligations related to the exercise of stock options described in the Form 4 filed on September 13, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.37 to $4.62, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc ("Mereo"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.

Read SEC document
September 12, 2024 Filed Sep 16, 2024 20:46 UTC Mereo BioPharma Group plc MREO · Entity 7264 SaleAmerican Depositary Shares representing Ordinary Shares 7,769 $4.47 $34,748.41
Disclosure

SEC source: 0000950170-24-106968 · ownership.xml · nonDerivative · entry 1

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,816

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F2 · shares: Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the 'Plan'), occurring on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.37 to $4.62, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc ("Mereo"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.

F6 · balance_after: The total amount of securities beneficially owned on the reporting person's Form 4 filed on September 13, 2024 has been reduced by 44,296, which reflects ADSs withheld by the Issuer in connection with the net settlement of the stock option exercise on September 11, 2024 and inadvertently omitted from the September 13, 2024 filing. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3.

Read SEC document
September 11, 2024 Filed Sep 13, 2024 16:47 UTC Mereo BioPharma Group plc MREO · Entity 7264 Exercise / conversionShare Options (Right to buy) · Derivative 75,000 $1.01 Strike: $1.01 $75,750.00
Disclosure

SEC source: 0000950170-24-106413 · ownership.xml · derivative · entry 6

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: American Depository Shares · 75,000 shares

Expires 2033-01-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 240,000 options were issued on 01/25/2023 and 25% of the shares underlying this award became exercisable on January 25, 2024, with the remainder vesting in equal monthly installments thereafter.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Read SEC document
September 11, 2024 Filed Sep 13, 2024 16:47 UTC Mereo BioPharma Group plc MREO · Entity 7264 Exercise / conversionShare Options (Right to buy) · Derivative 93,333 $1.40 Strike: $1.40 $130,666.20
Disclosure

SEC source: 0000950170-24-106413 · ownership.xml · derivative · entry 5

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: American Depository Shares · 93,333 shares

Expires 2032-01-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 160,000 options were issued on 01/14/2022 and 25% of the shares underlying this award became exercisable on January 14, 2023, with the remainder vesting in equal monthly installments thereafter.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Read SEC document
September 11, 2024 Filed Sep 13, 2024 16:47 UTC Mereo BioPharma Group plc MREO · Entity 7264 Exercise / conversionPerformance Based Restricted Stock Unit · Derivative 40,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-24-106413 · ownership.xml · derivative · entry 4

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: American Depository Shares · 40,000 shares

Expires 2025-01-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Read SEC document
September 11, 2024 Filed Sep 13, 2024 16:47 UTC Mereo BioPharma Group plc MREO · Entity 7264 Exercise / conversionAmerican Depositary Shares representing Ordinary Shares 75,000 $1.01 $75,750.00
Disclosure

SEC source: 0000950170-24-106413 · ownership.xml · nonDerivative · entry 3

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 242,881

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Read SEC document
September 11, 2024 Filed Sep 13, 2024 16:47 UTC Mereo BioPharma Group plc MREO · Entity 7264 Exercise / conversionAmerican Depositary Shares representing Ordinary Shares 93,333 $1.40 $130,666.20
Disclosure

SEC source: 0000950170-24-106413 · ownership.xml · nonDerivative · entry 2

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,881

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Read SEC document
September 11, 2024 Filed Sep 13, 2024 16:47 UTC Mereo BioPharma Group plc MREO · Entity 7264 Exercise / conversionAmerican Depositary Shares representing Ordinary Shares 40,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-106413 · ownership.xml · nonDerivative · entry 1

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,548

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F2 · shares: Represents performance-based restricted stock unit earned under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on September 11, 2024 based on satisfaction of ADS price threshold values over a two year performance period.

Read SEC document
June 26, 2024 Filed Jun 27, 2024 16:15 UTC Mereo BioPharma Group plc MREO · Entity 7264 SaleAmerican Depositary Shares representing Ordinary Shares 22,968 $3.39 $77,935.02
Disclosure

SEC source: 0000950170-24-078462 · ownership.xml · nonDerivative · entry 2

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,548

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F2 · shares: Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.28 to $3.51, inclusive.

Read SEC document
June 25, 2024 Filed Jun 27, 2024 16:15 UTC Mereo BioPharma Group plc MREO · Entity 7264 SaleAmerican Depositary Shares representing Ordinary Shares 10,134 $3.69 $37,433.98
Disclosure

SEC source: 0000950170-24-078462 · ownership.xml · nonDerivative · entry 1

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,516

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F2 · shares: Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.60 to $3.805, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc ("Mereo"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.

Read SEC document
June 21, 2024 Filed Jun 25, 2024 18:13 UTC Mereo BioPharma Group plc MREO · Entity 7264 Exercise / conversionPerformance Based Restricted Stock Unit · Derivative 60,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-24-077479 · ownership.xml · derivative · entry 2

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: American Depository Shares · 60,000 shares

Expires 2025-01-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Read SEC document
June 21, 2024 Filed Jun 25, 2024 18:13 UTC Mereo BioPharma Group plc MREO · Entity 7264 Exercise / conversionAmerican Depositary Shares representing Ordinary Shares 60,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-077479 · ownership.xml · nonDerivative · entry 1

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,650

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F2 · shares: Represents performance-based restricted stock unit ("PSU") earned under the issuer's 2019 Employee Incentive Plan (the "Plan") that vested on June 21, 2024 based on satisfaction of ADS price threshold values over a two year performance period (expiring on January 1, 2025).

Read SEC document
May 22, 2024 Filed May 23, 2024 21:54 UTC Mereo BioPharma Group plc MREO · Entity 7264 Exercise / conversionShare Options (Right to buy) · Derivative 75,000 $1.01 Strike: $1.01 $75,750.00
Disclosure

SEC source: 0000950170-24-064274 · ownership.xml · derivative · entry 8

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: American Depositary Shares · 75,000 shares

Expires 2033-01-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Ms. Hughes-Wilson sold a total of 100,432 ADSs solely to pay a tax obligation, and all proceeds are being used for such taxes.

F5 · derivative.exercise_date: 240,000 options were issued on 01/25/2023 and 25% of the shares underlying this award became exercisable on January 25, 2024, with the remainder vesting in equal monthly installments thereafter.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Read SEC document
May 22, 2024 Filed May 23, 2024 21:54 UTC Mereo BioPharma Group plc MREO · Entity 7264 Exercise / conversionShare Options (Right to buy) · Derivative 93,333 $1.40 Strike: $1.40 $130,666.20
Disclosure

SEC source: 0000950170-24-064274 · ownership.xml · derivative · entry 7

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: American Depositary Shares · 93,333 shares

Expires 2032-01-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Ms. Hughes-Wilson sold a total of 100,432 ADSs solely to pay a tax obligation, and all proceeds are being used for such taxes.

F4 · derivative.exercise_date: 160,000 options were issued on 01/14/2022 and 25% of the shares underlying this award became exercisable on January 14, 2023, with the remainder vesting in equal monthly installments thereafter.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Read SEC document
May 22, 2024 Filed May 23, 2024 21:54 UTC Mereo BioPharma Group plc MREO · Entity 7264 Tax withholdingAmerican Depositary Shares representing Ordinary Shares 24,918 $1.01 $25,167.18
Disclosure

SEC source: 0000950170-24-064274 · ownership.xml · nonDerivative · entry 6

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,650

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F2 · kind: Ms. Hughes-Wilson sold a total of 100,432 ADSs solely to pay a tax obligation, and all proceeds are being used for such taxes.

Read SEC document
May 22, 2024 Filed May 23, 2024 21:54 UTC Mereo BioPharma Group plc MREO · Entity 7264 SaleAmerican Depositary Shares representing Ordinary Shares 50,082 $2.94 $147,241.08
Disclosure

SEC source: 0000950170-24-064274 · ownership.xml · nonDerivative · entry 5

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,568

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F2 · kind: Ms. Hughes-Wilson sold a total of 100,432 ADSs solely to pay a tax obligation, and all proceeds are being used for such taxes.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $2.88 to $3.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges

Read SEC document
May 22, 2024 Filed May 23, 2024 21:54 UTC Mereo BioPharma Group plc MREO · Entity 7264 Exercise / conversionAmerican Depositary Shares representing Ordinary Shares 75,000 $1.01 $75,750.00
Disclosure

SEC source: 0000950170-24-064274 · ownership.xml · nonDerivative · entry 4

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,650

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F2 · kind: Ms. Hughes-Wilson sold a total of 100,432 ADSs solely to pay a tax obligation, and all proceeds are being used for such taxes.

Read SEC document
May 22, 2024 Filed May 23, 2024 21:54 UTC Mereo BioPharma Group plc MREO · Entity 7264 Tax withholdingAmerican Depositary Shares representing Ordinary Shares 42,983 $1.40 $60,176.20
Disclosure

SEC source: 0000950170-24-064274 · ownership.xml · nonDerivative · entry 3

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,650

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F2 · kind: Ms. Hughes-Wilson sold a total of 100,432 ADSs solely to pay a tax obligation, and all proceeds are being used for such taxes.

Read SEC document
May 22, 2024 Filed May 23, 2024 21:54 UTC Mereo BioPharma Group plc MREO · Entity 7264 SaleAmerican Depositary Shares representing Ordinary Shares 50,350 $2.99 $150,546.50
Disclosure

SEC source: 0000950170-24-064274 · ownership.xml · nonDerivative · entry 2

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,633

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F2 · kind: Ms. Hughes-Wilson sold a total of 100,432 ADSs solely to pay a tax obligation, and all proceeds are being used for such taxes.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $2.88 to $3.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges

Read SEC document
May 22, 2024 Filed May 23, 2024 21:54 UTC Mereo BioPharma Group plc MREO · Entity 7264 Exercise / conversionAmerican Depositary Shares representing Ordinary Shares 93,333 $1.40 $130,666.20
Disclosure

SEC source: 0000950170-24-064274 · ownership.xml · nonDerivative · entry 1

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,983

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F2 · kind: Ms. Hughes-Wilson sold a total of 100,432 ADSs solely to pay a tax obligation, and all proceeds are being used for such taxes.

Read SEC document
January 25, 2024 Filed Jan 26, 2024 16:15 UTC Mereo BioPharma Group plc MREO · Entity 7264 GrantShare Options (Right to buy) · Derivative 196,000 $0.00 Strike: $3.36 $0.00
Disclosure

SEC source: 0000950170-24-007937 · ownership.xml · derivative · entry 1

Hughes-Wilson Alexandra · CIK 0002005875 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 196,000

Underlying: American Depository Shares · 196,000 shares

Expires 2034-01-25

F1 · derivative.exercise_date: 25% of the shares underlying this share option will vest and become exercisable on January 25, 2025, with the remainder vesting in equal monthly installments for the three years thereafter.

F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.